Search Results - David Sommerhalder
- Showing 1 - 4 results of 4
-
1
472 BDB001, a toll-like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid... by Alexander Chung, Omid Hamid, Manish Patel, Drew Rasco, Robert Andtbacka, Anthony Tolcher, Melissa Johnson, David Sommerhalder, Lixin Li
Published in Journal for ImmunoTherapy of Cancer (2021-11-01)Article -
2
751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor by Scott Daigle, Sunil Sharma, Xinyan Zhang, Martin Gutierrez, Patricia Fraser, David Sommerhalder, Scott Boiko, Esha A Gangolli, Bhaskar Srivastava, Frank G Basile, Marcus Noel, Amanda Hoerres, Nawaid Rana, Rama Balaraman
Published in Journal for ImmunoTherapy of Cancer (2023-11-01)Article -
3
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors by Gerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, Jyoti Malhotra, Saeed Sadeghi, Arash Rezazadeh Kalebasty, Lauren Wood, Faisal Rahman, Elizabeth Li, Yvonne Pak, Maya Khalil, Alexander I. Spira, David Sommerhalder, Ignacio Garrido-Laguna, David S. Hong
Published in npj Precision Oncology (2026-02-01)Get full text
Article -
4
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results by David A. Braun, Marcus S. Noel, Ryan H. Moy, Kurt Demel, Martin Gutierrez, Sunil Sharma, Arif Hussain, Shirish Gadgeel, Julio Peguero, Toni K. Choueiri, Hamid Emamekhoo, Brian Van Tine, Rama Balaraman, GiNell Elliott, Sritama Nath, Scott R. Daigle, Pavan Kumar, Anita Scheuber, David Sommerhalder
Published in Cell Reports Medicine (2026-05-01)Get full text
Article